Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Gi Innovation Inc. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are being handled by 3 distinct examiners, indicating a completely decentralized review process where each active application is subject to a different examiner's scrutiny. This lack of overlap among examiners means that the applicant must prepare for 3 potentially different sets of examination priorities and styles.
The prosecution is spread across 3 distinct art units, which suggests that the company's research in Biotechnology & Pharmaceuticals touches upon multiple specialized fields. STOICA, ELLY GERALD is the busiest examiner for the portfolio, currently overseeing 1 pending office action. Because the busiest examiner handles only 1 pending office action, the workload is distributed evenly across the 3 distinct examiners currently engaged with the portfolio.
For patent practitioners, the involvement of 3 distinct art units means that the 3 pending office actions may be subject to different internal guidelines or average pendency rates. The fact that 3 distinct examiners are involved for only 3 pending office actions highlights a high degree of variety in the prosecution landscape. Success in this portfolio requires a tailored approach for each application to satisfy the specific requirements of STOICA, ELLY GERALD and the other two officials.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 1 | 66.8% | +22.6% |
| REGLAS, GEORGIANA C | 1 | 39.2% | +33.4% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18003123 | FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF | D' AMBROSIO, THEA | 53d overdue |
| 18499840 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING FUSION PROTEIN INCLUDING IL-2 PROTEIN AND CD80 PROTEIN AND ANTICANCER DRUG | STOICA, ELLY GERALD | — |
| 18549558 | FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR | REGLAS, GEORGIANA C | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1651 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18499840 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING FUSION PROTEIN INCLUDING IL-2 PROTEIN AND CD80 PROTEIN AND ANTICANCER DRUG | STOICA, ELLY GERALD | 1647 | §112DP | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18549558 | FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR | REGLAS, GEORGIANA C | 1651 | §103DP | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18003123 | FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF | D' AMBROSIO, THEA | 1654 | §103 | Non-Final OA | 53d overdue | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGi Innovation Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Elly Gerald Stoica has the most, with 1 of Gi Innovation Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
